Identifying novel skeletal muscle pathways that can restore PGC1α activity and improve mitochondrial function and oxidative capacity is necessary, so that these novel factors can be potentially harnessed therapeutically to reverse prediabetes and prevent progression to frank T2D. This evidence concerns the gene PPARGC1A and type 2 diabetes mellitus.